Ikena Oncology, Inc.
IKNA
$1.17
-$0.04-3.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 659.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 659.00K |
| Cost of Revenue | 4.58M | 6.82M | 9.43M | 9.65M | 14.27M |
| Gross Profit | -4.58M | -6.82M | -9.43M | -9.65M | -13.62M |
| SG&A Expenses | 7.60M | 4.78M | 5.31M | 6.00M | 8.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.18M | 11.60M | 15.14M | 15.64M | 22.57M |
| Operating Income | -12.18M | -11.60M | -15.14M | -15.64M | -21.91M |
| Income Before Tax | -9.07M | -10.22M | -13.67M | -16.12M | -19.65M |
| Income Tax Expenses | 53.00K | 10.00K | 62.00K | 27.00K | -162.00K |
| Earnings from Continuing Operations | -9.12M | -10.23M | -13.73M | -16.15M | -19.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.12M | -10.23M | -13.73M | -16.15M | -19.49M |
| EBIT | -12.18M | -11.60M | -15.14M | -15.64M | -21.91M |
| EBITDA | -12.09M | -11.51M | -15.05M | -15.43M | -21.60M |
| EPS Basic | -0.19 | -0.21 | -0.28 | -0.33 | -0.41 |
| Normalized Basic EPS | -0.11 | -0.12 | -0.17 | -0.18 | -0.26 |
| EPS Diluted | -0.19 | -0.21 | -0.28 | -0.33 | -0.41 |
| Normalized Diluted EPS | -0.11 | -0.12 | -0.17 | -0.18 | -0.26 |
| Average Basic Shares Outstanding | 48.26M | 48.26M | 48.26M | 48.26M | 47.87M |
| Average Diluted Shares Outstanding | 48.26M | 48.26M | 48.26M | 48.26M | 47.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |